Want to see AU:NOX full AI Analyst Report?
NOX Stock Chart & Stats
AU$0.10
>-AU$0.01(-7.87%)
At close: 4:00 PM EDT
AU$0.10
>-AU$0.01(-7.87%)
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.11
Previous CloseN/A
Volume10.31K
Average Volume (3M)67.02K
Market Cap
AU$15.05M
Enterprise ValueAU$30.46M
Total Cash (Recent Filing)AU$293.57K
Total Debt (Recent Filing)AU$4.57M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Mar 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding307,237,950
10 Day Avg. Volume78,340
30 Day Avg. Volume67,020
Financial Highlights & Ratios
PEG Ratio0.57
Price to Book (P/B)-7.08
Price to Sales (P/S)18.11
P/FCF Ratio-9.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Oncology R&D FocusA focused oncology and immuno-oncology strategy gives Noxopharm a clear therapeutic identity and aligns its research with a large, persistent medical need. Progressing drug candidates through preclinical and clinical development, including combination strategies, provides potential for longer-term pipeline value.
Narrower Operating LossThe meaningful reduction in operating losses indicates some improvement in cost control or expense intensity, even though profitability has not been reached. If maintained while development programs advance, this trend could reduce the pace of future losses and improve operating leverage over coming periods.
Improved Cash BurnA substantially smaller cash outflow in 2026 is a constructive change for an R&D-heavy biotech because it can extend the period before additional capital is required. Continued discipline would preserve more resources for clinical development, although cash generation remains negative overall.
Bears Say
Persistent UnprofitabilityPersistent operating and net losses, combined with a sharp recent revenue contraction, show that the company has not yet established a self-sustaining commercial earnings base. This limits operating leverage and leaves future results dependent on successful development, commercialization, or further funding.
Negative Equity And Higher DebtNegative stockholders’ equity and rising debt indicate accumulated financial strain and materially reduce balance-sheet flexibility. This structure can constrain investment in research programs, increase dependence on capital raising, and make it harder for the company to absorb setbacks while losses continue.
Ongoing External Funding NeedContinually negative operating and free cash flow means internal operations are not funding the company’s research commitments. Dependence on external financing can dilute existing holders or increase obligations, while also making development progress more vulnerable to capital availability.
Noxopharm Ltd. News
NOX FAQ
What was Noxopharm Ltd.’s price range in the past 12 months?
Noxopharm Ltd. lowest share price was AU$0.05 and its highest was AU$0.11 in the past 12 months.
What is Noxopharm Ltd.’s market cap?
Noxopharm Ltd.’s market cap is AU$15.05M.
When is Noxopharm Ltd.’s upcoming earnings report date?
Noxopharm Ltd.’s upcoming earnings report date is Mar 02, 2027 which is in 122 days.
How were Noxopharm Ltd.’s earnings last quarter?
Noxopharm Ltd. released its earnings results on Aug 28, 2026. The company reported -AU$0.009 earnings per share for the quarter.
Is Noxopharm Ltd. overvalued?
According to Wall Street analysts Noxopharm Ltd.’s price is currently Overvalued.
Does Noxopharm Ltd. pay dividends?
Noxopharm Ltd. does not currently pay dividends.
What is Noxopharm Ltd.’s EPS estimate?
Noxopharm Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Noxopharm Ltd. have?
Noxopharm Ltd. has 307,237,950 shares outstanding.
What happened to Noxopharm Ltd.’s price movement after its last earnings report?
Noxopharm Ltd. reported an EPS of -AU$0.009 in its last earnings report. Following the earnings report the stock price went down -6.667%.
Which hedge fund is a major shareholder of Noxopharm Ltd.?
Currently, no hedge funds are holding shares in AU:NOX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Noxopharm Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:NOX Sentiment 100%
Sector Average 64%
Sector Average 64%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Fundamentals
Return on Equity
186.62%
Trailing 12-Months
Asset Growth
-59.90%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Noxopharm Ltd.
Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvant therapy designed to augment the effectiveness of chemotherapy and radiotherapy in treating late-stage cancers. Beyond Veyonda, the company's robust development pipeline encompasses several key programs: The DARRT program, currently in Phase 1b/2a clinical trials, is addressing metastatic castration-resistant prostate cancer and other solid tumors. The LuPIN program explores a combined therapy of Veyonda and 177Lu-PSMA-617 for advanced prostate cancer. The IONIC program combines Veyonda with Bristol Myers Squibb's checkpoint inhibitor, Opdivo, targeting various solid tumor types. Its Chemotherapy Enhancement Program (CEP) integrates Veyonda with carboplatin for patients suffering from refractory solid tumors in areas such as the breast, head and neck, lung, prostate, and ovaries. Furthermore, the NOXCOVID Program is conducting a dose escalation and expansion study of NOX66 for the treatment of COVID-19 infection. The company is also investigating potential treatments for pancreatic cancer and glioblastoma. Noxopharm collaborates with the Hudson Institute of Medical Research and The Australian National University on the research and development of therapeutic drugs for inflammatory disorders. Incorporated in 2015, the company's operations are based in Chatswood, Australia.
Technical Analysis
Prescient Therapeutics Limited
―
Telix Pharmaceuticals
―
Race Oncology Ltd.
―
Clarity Pharmaceuticals Ltd.
―
Radiopharm Theranostics Limited
―